Abstract
In a recent meta-analysis of the risks and benefits of anti-tumour necrosis factor (TNF) therapies in patients with psoriatic arthritis, Saad et al. found that adalimumab, etanercept and infliximab were all significantly more effective than placebo for all outcome measures analyzed. There were no differences between these anti-TNF inhibitors in achieving the American College of Rheumatology criteria for 20% improvement (ACR20) response for joint disease. A difference in the efficacy of the anti-TNF agents for treatment of skin manifestations was reported; however, this difference did not reach statistical significance. Analysis of other disease manifestations would have been interesting, as there is a clinical perception of a better response to treatment with anti-TNF antibodies (i.e. adalimumab and infliximab) versus the TNF receptor (i.e. etanercept). When comparing the anti-TNF agents with placebo in terms of safety, the only significant difference was an increased incidence of injection-site reactions associated with etanercept therapy. As all three drugs were shown to be equally effective in the management of psoriatic arthritis, patients should be allowed to make treatment choices based on whether they prefer the flexibility of self injection or whether they find repeated injections unacceptable.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study
Clinical Rheumatology Open Access 01 March 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bond SJ et al. (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66: 370–376
Gladman DD et al. (1998) Mortality studies in psoriatic arthritis: results from a single outpatient centre. II. Prognostic indicators for death. Arthritis Rheum 41: 1103–1110
Soriano ER and McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33: 1422–1430
Kaltwasser JP et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939–1950
Saad AA et al. (2008) Risk and benefits of tumour necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35: 883–890
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has consulted to Abbott, Amgen, Wyeth, Centocor and Schering, participated in several of these companies' trials, and received grant support for research from these companies.
Rights and permissions
About this article
Cite this article
Gladman, D. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Rev Rheumatol 4, 510–511 (2008). https://doi.org/10.1038/ncprheum0880
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0880
This article is cited by
-
Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs
Clinical Reviews in Allergy & Immunology (2018)
-
Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management
Current Rheumatology Reports (2015)
-
The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study
Clinical Rheumatology (2011)
-
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs
Clinical Rheumatology (2010)